A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is a single centre, single dose pharmacokinetic/safety study in male and female
asthmatic subjects. Subjects will receive a single dose of 10 mg of AER 001 administered as a
dry powder using a handheld device. The goals of this study are to understand the
pharmacokinetics and safety of AER 001 administered as a dry powder in mild to moderate
asthmatics.